Abstract

Background: The turnaround times for phenotypic tests used to monitor the bacterial load of Mycobacterium tuberculosis, in both clinical and preclinical studies, are delayed by the organism’s slow growth in culture media. The existence of differentially culturable populations of M. tuberculosis may result in an underestimate of the true number. Moreover, culture methods are susceptible to contamination resulting in loss of critical data points. Objectives: We report the adaptation of our robust, culture-free assay utilising 16S ribosomal RNA, developed for sputum, to enumerate the number of bacteria present in animal tissues as a tool to improve the read-outs in preclinical drug efficacy studies. Methods: Initial assay adaptation was performed using naïve mouse lungs spiked with known quantities of M. tuberculosis and an internal RNA control. Tissues were homogenised, total RNA extracted, and enumeration performed using RT-qPCR. We then evaluated the utility of the assay, in comparison to bacterial counts estimated using growth assays on solid and liquid media, to accurately inform bacterial load in tissues from M. tuberculosis-infected mice before and during treatment with a panel of drug combinations. Results: When tested on lung tissues derived from infected mice, the MBL assay produced comparable results to the bacterial counts in solid culture (colony forming units: CFU). Notably, under specific drug treatments, the MBL assay was able to detect a significantly higher number of M. tuberculosis compared to CFU, likely indicating the presence of bacteria that were unable to produce colonies in solid-based culture. Additionally, growth recovery in liquid media using the most probable number (MPN) assay was able to account for the discrepancy between the MBL assay and CFU number, suggesting that the MBL assay detects differentially culturable sub-populations of M. tuberculosis. Conclusions: The MBL assay can enumerate the bacterial load in animal tissues in real time without the need to wait for extended periods for cultures to grow. The readout correlates well with CFUs. Importantly, we have shown that the MBL is able to measure specific populations of bacteria not cultured on solid agar. The adaptation of this assay for preclinical studies has the potential to decrease the readout time of data acquisition from animal experiments and could represent a valuable tool for tuberculosis drug discovery and development.

Highlights

  • Tuberculosis (TB) continues to be one of the top ten causes of death worldwide and in 2020 alone more than 1.5 million people died of the disease [1]

  • We developed and trialled the molecular bacterial load (MBL) assay for enumeration of live TB bacilli from sputum using the detection of 16S ribosomal RNA [18,19]

  • In order to transfer the MBL assay conversion scale for the enumeration of bacterial load in sputum to infected tissues, we first used uninfected mouse lungs that were spiked with various concentrations of M. tuberculosis H37Rv and Internal Control (IC) RNA

Read more

Summary

Introduction

Tuberculosis (TB) continues to be one of the top ten causes of death worldwide and in 2020 alone more than 1.5 million people died of the disease [1]. Drug-sensitive cases of TB are treated with a combination of four first-line drugs (isoniazid: INH, rifampicin: RIF, ethambutol: EMB, and pyrazinamide: PZA) for 6 months with a cure rate of more than 80% [2]. Drug-resistant TB is an urgent health emergency with higher costs associated with its treatment and cure rates for XDR-TB are below 40%. Since treatment options for drug-resistant TB are limited, there is an urgent need to develop new drugs and drug regimens as well as other therapeutics to tackle the disease, increase cure rates and reduce the treatment course duration.

Objectives
Methods
Results
Conclusion
Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.